Frequency Therapeutics, Inc. FREQ
Set alert
0.30 0.00 0.00%
At close · Nov 3
0.28 Day range 0.32
52-week range unavailable
- Open
- 0.29
- Prev close
- 0.2996
- Mkt cap
- 10.94M
- Vol
- 309.16K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.28
- High
- 0.32
- Forward P/E
- -0.26
- Beta
- 0.00
- Short ratio
- 3.51
- Inst. own
- 14.12%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 14, 2023
- 50-d avg
- 0.350724
- 200-d avg
- 0.639007
- 1y target
- 0.50
2Y chart
Events in this range
- Aug 9, 2022Earnings: —; estimate -0.69; surprise —%
- Nov 1, 2022Rating: Baird · — → Outperform
- Nov 8, 2022Earnings: —; estimate -0.61; surprise —%
- Dec 7, 2022Rating: Chardan Capital · — → Buy
- Feb 13, 2023Downgrade: Oppenheimer · Outperform → Perform
- Feb 13, 2023Rating: Baird · — → Outperform
- Feb 14, 2023Downgrade: Chardan Capital · Buy → Neutral
- Mar 10, 2023Earnings: —; estimate -0.65; surprise —%
- May 12, 2023Earnings: —; estimate -0.39; surprise —%
- Aug 10, 2023Earnings: —; estimate -0.44; surprise —%
- Sep 25, 2023Downgrade: Baird · Outperform → Neutral
Signals (69)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 27, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 24, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 19, 2023 | 3 years ago |
| RSI: Oversold | Oct 19, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 16, 2023 | 3 years ago |
| RSI: Oversold | Oct 12, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 4, 2023 | 3 years ago |
| RSI: Oversold | Oct 4, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 28, 2023 | 3 years ago |
| RSI: Oversold | Sep 22, 2023 | 3 years ago |
| RSI: Oversold | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Aug 22, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 16, 2023 | 3 years ago |
| MACD: Buy Signal | Aug 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 27, 2023 | 3 years ago |
| RSI: Overbought | Jul 14, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 22, 2023 | 3 years ago |
| SMA: Bearish | Jun 13, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| RSI: Oversold | Apr 20, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| RSI: Oversold | Feb 13, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 27, 2023 | 3 years ago |
| RSI: Overbought | Jan 23, 2023 | 3 years ago |
| RSI: Overbought | Jan 19, 2023 | 3 years ago |
| RSI: Overbought | Jan 10, 2023 | 3 years ago |
| RSI: Overbought | Dec 28, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 23, 2022 | 3 years ago |
| SMA: Bullish | Dec 22, 2022 | 3 years ago |
| SMA: Bearish | Dec 21, 2022 | 3 years ago |
| SMA: Bullish | Dec 20, 2022 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 6, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Nov 22, 2022 | 3 years ago |
| SMA: Bearish | Nov 21, 2022 | 3 years ago |
| SMA: Bullish | Nov 18, 2022 | 3 years ago |
| SMA: Bullish | Nov 18, 2022 | 3 years ago |
| SMA: Bearish | Nov 17, 2022 | 3 years ago |
| SMA: Bearish | Nov 17, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 17, 2022 | 3 years ago |
| SMA: Bullish | Nov 9, 2022 | 3 years ago |
| SMA: Bearish | Nov 8, 2022 | 3 years ago |
| SMA: Bullish | Nov 3, 2022 | 3 years ago |
| RSI: Overbought | Nov 3, 2022 | 3 years ago |
| SMA: Bullish | Nov 2, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 31, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 19, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 13, 2022 | 4 years ago |
| SMA: Bearish | Sep 14, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 25, 2022 | 4 years ago |
| RSI: Overbought | Jul 8, 2022 | 4 years ago |
| SMA: Bullish | Jun 23, 2022 | 4 years ago |
| MACD: Buy Signal | Apr 14, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 8, 2022 | 4 years ago |
| RSI: Oversold | Apr 7, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 16, 2022 | 4 years ago |
| RSI: Oversold | Feb 22, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 7, 2022 | 4 years ago |
| SMA: Bearish | Feb 3, 2022 | 4 years ago |
| SMA: Bullish | Jan 31, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 28, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 26, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 25, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 18, 2022 | 4 years ago |
Key statistics
- Market cap
- 10.94M
- Enterprise value
- 512.86M
- Trailing P/E
- 0.00
- Forward P/E
- -0.26
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.30
- EPS (TTM)
- -1.90
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -17.51M
- Total cash
- 41.72M
- Total debt
- 1.43M
- Return on equity
- -99.93%
- Shares outstanding
- 36.52M
- Short % of float
- 1.06%
- 50-day average
- 0.350724
- 200-day average
- 0.639007
Analyst view
Consensus: hold
Hold
Price target (mean) 0.50
Next earnings
Nov 14, 2023
Expected Nov 14, 2023. Consensus EPS estimate -0.35.
Financials — quick view
FREQ Revenue — quarterly 0
FREQ Net income — quarterly -10.80M
FREQ EPS — quarterly -0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.44 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | -0.39 | — | — | — |
| Mar 10, 2023 | Dec 1, 2022 | -0.65 | — | — | — |
| Nov 8, 2022 | Sep 1, 2022 | -0.61 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -0.69 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2023 | Baird | down | Outperform | Neutral |
| Feb 14, 2023 | Chardan Capital | down | Buy | Neutral |
| Feb 13, 2023 | Oppenheimer | down | Outperform | Perform |
| Feb 13, 2023 | Baird | main | — | Outperform |
| Dec 7, 2022 | Chardan Capital | init | — | Buy |
| Nov 1, 2022 | Baird | init | — | Outperform |
About Frequency Therapeutics, Inc.
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- frequencytx.com
News
- Frequency Exchange Announces Appointment Of Friesen To Board Of Directors
- Fremedica Launches Nikki Lyme Wellness Program Through Ergopathics Network
- Frequency Exchange Corp. Appoints Gail Edgell To Advisory Board
- Frequency Exchange Appoints Michael MOE To Advisory Board
- NIKKI's Efficacy in Overcoming Lyme Disease to be Presented at 2024 Leap into Health Conference
- UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
- Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
- FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ
- Stocks That Hit 52-Week Lows On Wednesday
- Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results
Your note
Sign in to keep a note on FREQ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARNOLD WENDY S | Officer | Sale | Jul 5, 2022 | 21,186 |
| BARBERICH TIMOTHY J | Director | Stock Gift | Dec 23, 2020 | 80,650 |
| LANGER ROBERT S JR. | Director | Stock Gift | Nov 16, 2020 | 240,021 |
| LEBEL CARL | Officer | Sale | Jul 5, 2022 | 26,343 |
| LOOSE CHRISTOPHER R | Officer | Sale | Jul 27, 2023 | 183,650 |
| LUCCHINO DAVID L. | Chief Executive Officer | Sale | Aug 20, 2023 | 633,744 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 4.73% | 1,727,566 | 597.74K | Jun 29, 2023 |
| Blackrock Inc. | 3.35% | 1,224,091 | 423.54K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 1.12% | 409,200 | 141.58K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.90% | 327,516 | 113.32K | Jun 29, 2023 |
| Gts Securities LLC | 0.61% | 223,278 | 77.25K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 0.39% | 140,945 | 48.77K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.41% | 1,246,700 | 431.36K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.23% | 448,505 | 155.18K | Jun 29, 2023 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 1.17% | 428,010 | 149.80K | May 30, 2023 |
| BlackRock Health Sciences Term Trust | 0.63% | 231,775 | 80.19K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.51% | 185,128 | 64.79K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.15% | 54,830 | 19.19K | May 30, 2023 |